These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 35841105)

  • 1. A global, cross-sectional survey of patient-reported outcomes, disease burden, and quality of life in epidermolysis bullosa simplex.
    So JY; Fulchand S; Wong CY; Li S; Nazaroff J; Gorell ES; de Souza MP; Murrell DF; Teng JM; Chiou AS; Tang JY
    Orphanet J Rare Dis; 2022 Jul; 17(1):270. PubMed ID: 35841105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hindi translation and validation of quality of life score in Indian patients with epidermolysis bullosa; and its correlation with the clinical severity assessment scores: A cross-sectional study.
    Bishnoi A; Manjunath S; Kishore K; De D; Handa S; Murrell DF; Mahajan R
    Indian J Dermatol Venereol Leprol; 2022; 88(2):177-183. PubMed ID: 34491666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-reported outcomes and quality of life in recessive dystrophic epidermolysis bullosa: A global cross-sectional survey.
    Eng VA; Solis DC; Gorell ES; Choi S; Nazaroff J; Li S; de Souza MP; Murrell DF; Marinkovich MP; Tang JY
    J Am Acad Dermatol; 2021 Nov; 85(5):1161-1167. PubMed ID: 32199895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the Timing of Milestone Clinical Events in Patients With Epidermolysis Bullosa From North America.
    Feinstein JA; Jambal P; Peoples K; Lucky AW; Khuu P; Tang JY; Lara-Corrales I; Pope E; Wiss K; Hook KP; Levin LE; Morel KD; Paller AS; McCuaig CC; Powell J; Eichenfield LF; Price H; Levy ML; Schachner LA; Browning JC; Bayliss S; Jahnke M; Shwayder T; Glick SA; Bruckner AL
    JAMA Dermatol; 2019 Feb; 155(2):196-203. PubMed ID: 30586139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported outcomes and quality of life in dominant dystrophic epidermolysis bullosa: A global cross-sectional survey.
    Fulchand S; Harris N; Li S; Barriga M; Gorell E; De Souza M; Murrell D; Marinkovich MP; Krishna Yenamandra V; Tang JY
    Pediatr Dermatol; 2021 Sep; 38(5):1198-1201. PubMed ID: 34515355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plantar involvement correlates with obesity, pain and impaired mobility in epidermolysis bullosa simplex: a retrospective cohort study.
    Reimer-Taschenbrecker A; Hess M; Hotz A; Fischer J; Bruckner-Tuderman L; Has C
    J Eur Acad Dermatol Venereol; 2021 Oct; 35(10):2097-2104. PubMed ID: 33960018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Quality of Life in Epidermolysis Bullosa" and "Epidermolysis Bullosa Burden of Disease": Italian translation, cultural adaptation, and pilot testing of two disease-specific questionnaires.
    El Hachem M; Diociaiuti A; Zambruno G; Samela T; Ferretti F; Carnevale C; Linertová R; Bodemer C; Murrell DF; Abeni D
    Ital J Pediatr; 2024 Apr; 50(1):76. PubMed ID: 38637879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The challenges of living with and managing epidermolysis bullosa: insights from patients and caregivers.
    Bruckner AL; Losow M; Wisk J; Patel N; Reha A; Lagast H; Gault J; Gershkowitz J; Kopelan B; Hund M; Murrell DF
    Orphanet J Rare Dis; 2020 Jan; 15(1):1. PubMed ID: 31900176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Burden of itch in epidermolysis bullosa.
    Snauwaert JJ; Yuen WY; Jonkman MF; Moons P; Naulaers G; Morren MA
    Br J Dermatol; 2014 Jul; 171(1):73-8. PubMed ID: 24506095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Translation, cross-cultural adaptation and validation of the Quality of Life Evaluation in Epidermolysis Bullosa instrument in Brazilian Portuguese.
    Cestari T; Prati C; Menegon DB; Prado Oliveira ZN; Machado MC; Dumet J; Nakano J; Murrell DF
    Int J Dermatol; 2016 Feb; 55(2):e94-9. PubMed ID: 26474322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic literature review of the disease burden in patients with recessive dystrophic epidermolysis bullosa.
    Tang JY; Marinkovich MP; Lucas E; Gorell E; Chiou A; Lu Y; Gillon J; Patel D; Rudin D
    Orphanet J Rare Dis; 2021 Apr; 16(1):175. PubMed ID: 33849616
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pain and quality of life evaluation in patients with localized epidermolysis bullosa simplex.
    Brun J; Chiaverini C; Devos C; Leclerc-Mercier S; Mazereeuw J; Bourrat E; Maruani A; Mallet S; Abasq C; Phan A; Vabres P; Martin L; Bodemer C; Lagrange S; Lacour JP;
    Orphanet J Rare Dis; 2017 Jun; 12(1):119. PubMed ID: 28659151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psychometric Properties of the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa patient score (iscorEB-p): a patient-reported outcome measure.
    Salamon G; Strobl S; Field-Werners U; Diem A; Schwieger-Briel A; Pope E
    Br J Dermatol; 2024 Jun; 191(1):75-81. PubMed ID: 38261404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life in patients with epidermolysis bullosa.
    Tabolli S; Sampogna F; Di Pietro C; Paradisi A; Uras C; Zotti P; Castiglia D; Zambruno G; Abeni D
    Br J Dermatol; 2009 Oct; 161(4):869-77. PubMed ID: 19624546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ophthalmologic Approach in Epidermolysis Bullosa: A Cross-Sectional Study With Phenotype-Genotype Correlations.
    Mellado F; Fuentes I; Palisson F; I Vergara J; Kantor A
    Cornea; 2018 Apr; 37(4):442-447. PubMed ID: 29384803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoid use and effects in patients with epidermolysis bullosa: an international cross-sectional survey study.
    Schräder NHB; Gorell ES; Stewart RE; Duipmans JC; Harris N; Perez VA; Tang JY; Wolff AP; Bolling MC
    Orphanet J Rare Dis; 2021 Sep; 16(1):377. PubMed ID: 34488820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An analysis of the prevalence of osteoporosis and osteopenia in patients with epidermolysis bullosa: A cross-sectional study.
    Kang M; Chen JSC; Radjenovic M; Yang A; Feng GHY; Murrell DF
    Exp Dermatol; 2021 Nov; 30(11):1675-1685. PubMed ID: 33347654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Small molecule drug development for rare genodermatoses - evaluation of the current status in epidermolysis bullosa.
    Wally V; Reisenberger M; Kitzmüller S; Laimer M
    Orphanet J Rare Dis; 2020 Oct; 15(1):292. PubMed ID: 33076941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison study of outcome measures for epidermolysis bullosa: Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI) and the Instrument for Scoring Clinical Outcomes of Research for Epidermolysis Bullosa (iscorEB).
    Rogers CL; Gibson M; Kern JS; Martin LK; Robertson SJ; Daniel BS; Su JC; Murrell OGC; Feng G; Murrell DF
    JAAD Int; 2021 Mar; 2():134-152. PubMed ID: 34409361
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.